Top Industry Leaders in the Bone Metastasis Market
Latest Bone Metastasis Companies Updates:
Amgen Received FDA approval for EVENITY™ (romosozumab-hxc) Injection, a new bone-sparing agent offering dual mechanism of action for reducing the risk of skeletal-related events (SREs) in adults with advanced solid tumors and bone metastases.
Eli Lilly and Company Initiated Phase 3 clinical trial evaluating the efficacy and safety of Verzenio™ (abemaciclib) in combination with Xeloda™ (capecitabine) for treating patients with first-line metastatic or locally advanced gastric cancer with bone metastases.
AstraZeneca Expanded the label for Zoladex® (goserelin acetate) implant for prostate cancer, now including an indication for reducing the risk of SREs in men with hormone-naive metastatic prostate cancer.
Novartis Acquired Genmab A/S, gaining access to promising late-stage bispecific antibody drugs with potential applications in treating various cancers, including those with bone metastases.
Merck & Co., Inc. Partnered with University of California, San Francisco to develop and commercialize novel targeted therapies for bone metastases arising from specific cancer types.Roche Diagnostics: Collaborated with medical technology companies to develop AI-powered solutions for analyzing imaging data and predicting the risk of bone metastases in cancer patients.
List of Bone Metastasis Key companies in the market:
- F. Hoffmann-La Roche Ltd (Switzerland)
- Bayer AG (Germany)
- Merck & Co., Inc. (U.S.)
- Pfizer Inc. (U.S.)
- Novartis AG (Switzerland)
- Pharmalucence Inc. (England)
- Koninklijke Philips N.V. (the Netherlands)
- GENERAL ELECTRIC (U.S.)
- Siemens AG (Germany)
